Move Into AI Biopharma

The acquisition centers on Orchestra Bio, a drug development platform that applies AI to the pharmaceutical discovery process. The deal gives LG direct access to the platform's technology as it broadens its business portfolio beyond electronics and chemicals.

Details such as the transaction value and the size of the acquired organization were not provided in the available information.

Strategic Context

AI-based drug discovery has become an area of active investment for Korean conglomerates, combining capabilities in computing and life sciences. LG's purchase of the platform positions it to participate in that field, though further specifics on integration plans have not been disclosed.

The acquisition of the AI drug development platform Orchestra Bio is True.